Kyverna Therapeutics (KYTX) Cash from Investing Activities (2023 - 2026)

Kyverna Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$50.2 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 999.98% year-over-year to -$50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.8 million (up 51.41% YoY) and the FY2025 annual result came in at $40.0 million, up 124.87% from the prior year.
• Cash from Investing Activities was -$50.2 million for Q1 2026 at Kyverna Therapeutics, down from -$17.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $31.7 million in Q4 2023 and bottomed at -$122.9 million in Q1 2024.
• A 4-year average of -$13.8 million and a median of $676000.0 in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities tumbled 2263933.33% — and 2025, when it surged 3236.83%.
• Kyverna Therapeutics' Cash from Investing Activities stood at $31.7 million in 2023, then dropped by 7.76% to $29.2 million in 2024, then slumped by 159.16% to -$17.3 million in 2025, then tumbled by 190.4% to -$50.2 million in 2026.
• Business Quant data shows KYTX's Cash from Investing Activities at -$50.2 million in Q1 2026, -$17.3 million in Q4 2025, and $22.6 million in Q3 2025.